The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells

Zhang,Zhe; Liu,Ze-Bing; Ren,Wei-Min; Ye,Xuan-Guang; Zhang,You-Yuan

doi:10.3892/ijmm.2012.1059

The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells

Authors:
- Zhe Zhang
- Ze-Bing Liu
- Wei-Min Ren
- Xuan-Guang Ye
- You-Yuan Zhang
View Affiliations

Affiliations: Department of Integrated Therapy, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China, Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 200540, P.R. China
Published online on: July 12, 2012 https://doi.org/10.3892/ijmm.2012.1059
Pages: 856-862

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The miR-200 family was recently identified as a suppressor of epithelial-mesenchymal transition (EMT). The loss or gain of miR-200 family members is associated with cancer invasion. The epidermal growth factor receptor (EGFR) is overexpressed in the majority of anaplastic thyroid cancers (ATCs). The activation of EGFR by its ligand, epidermal growth factor (EGF), activates a signaling cascade that results in the enhanced migration and invasiveness of thyroid cancer cells. However, little is known about the potential interrelationships between EGF/EGFR, miR-200s and the induction of EMT or mesenchymal-epithelial transition (MET) processes. This study aimed to investigate the regulatory role of miR-200s in EMT modulation by EGF/EGFR. Using transfection, real-time reverse transcription PCR and western blot analysis, we found that the EGF treatment of Nthy-ori 3-1 thyroid follicular cells resulted in the downregulation of E-cadherin and the upregulation of vimentin. By contrast, EGFR silencing in SW1736 human thyroid carcinoma cells led to the upregulation of E-cadherin and the downregulation of vimentin. In addition, EGF signaling correlated with the reduced expression of miR-200s and the re-expression of miR-200s abrogated the effects of EGF treatment and restored an epithelial phenotype to EGF-induced Nthy-ori 3-1 cells. Conversely, the silencing of miR-200s in SW1736 cells overcame siEGFR-induced changes in gene expression and phenotype. In addition, we demonstrate that miR-200s play a key role in in vitro EGF/EGFR-mediated thyroid cell invasion and in EMT in vivo. We, therefore, provide a mechanistic link between the miR-200 family and EGF/EGFR, which suggests that miR-200 upregulation may serve as a novel therapeutic strategy for highly invasive thyroid cancers.

View Figures

View References

1.	G Riesco-EizaguirreP SantistebanNew insights in thyroid follicular cell biology and its impact in thyroid cancer therapyEndocr Relat Cancer14957977200710.1677/ERC-07-008518045949
2.	KN PatelAR ShahaPoorly differentiated and anaplastic thyroid cancerCancer Control13119128200616735986
3.	WB ZhongYC LiangCY WangTC ChangWS LeeLovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signalingEndocr Relat Cancer12615629200510.1677/erc.1.0101216172195
4.	L LarueA BellacosaEpithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathwaysOncogene2474437454200510.1038/sj.onc.120909116288291
5.	JP ThieryH AcloqueRY HuangMA NietoEpithelialmesenchymal transitions in development and diseaseCell139871890200910.1016/j.cell.2009.11.00719945376
6.	JJ ChristiansenAK RajasekaranReassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasisCancer Res6683198326200610.1158/0008-5472.CAN-06-041016951136
7.	JD BergstromB WestermarkNE HeldinEpidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cellsExp Cell Res259293299200010.1006/excr.2000.4967
8.	CT KuanCJ WikstrandDD BignerEGF mutant receptor vIII as a molecular target in cancer therapyEndocr Relat Cancer88396200110.1677/erc.0.008008311397666
9.	AK LarsenD OuaretK El OuadraniA PetitprezTargeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesisPharmacol Ther1318090201110.1016/j.pharmthera.2011.03.01221439312
10.	T CasconeMH HerynkL XuZ DuH KadaraMB NilssonCJ ObornYY ParkB ErezJJ JacobyUpregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinomaJ Clin Invest12113131328201110.1172/JCI4240521436589
11.	L Ferrer-SolerA Vazquez-MartinJ BrunetJA MenendezRD LlorensR ColomerAn update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleocytoplasmic trafficking of HER-ligands (Review)Int J Mol Med203102007
12.	V Sanz-MorenoC GaggioliM YeoJ AlbrenguesF WallbergA VirosS HooperR MitterCC FéralM CookROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stromaCancer Cell20229245201110.1016/j.ccr.2011.06.01821840487
13.	Z ZhangJH RenZY LiL NongG WuFasudil inhibits lung carcinoma-conditioned endothelial cell viability and migrationOncol Rep2715611566201222344855
14.	G MavriaY VercoulenM YeoH PatersonM KarasaridesR MaraisD BirdCJ MarshallERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesisCancer Cell93344200610.1016/j.ccr.2005.12.02116413470
15.	WB ZhongSP HsuPY HoYC LiangTC ChangWS LeeLovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathwayBiochem Pharmacol8216631672201110.1016/j.bcp.2011.08.02121907187
16.	Y KideraM TsubakiY YamazoeK ShojiH NakamuraM OgakiT SatouT ItohM IsozakiJ KanekoReduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho- associated coiled-coil containing protein kinase pathwayJ Exp Clin Cancer Res29127201010.1186/1756-9966-29-12720843370
17.	JA FoekensAM SieuwertsM SmidMP LookV de WeerdAW BoersmaJG KlijnEA WiemerJW MartensFour miRNAs associated with aggressiveness of lymph node-negative estrogen receptor-positive human breast cancerProc Natl Acad Sci USA1051302113026200810.1073/pnas.080330410518755890
18.	L MaJ Teruya-FeldsteinRA WeinbergTumour invasion and metastasis initiated by microRNA-10b in breast cancerNature449682688200710.1038/nature0617417898713
19.	PA GregoryAG BertEL PatersonSC BarryA TsykinG FarshidMA VadasY Khew-GoodallGJ GoodallThe miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1Nat Cell Biol10593601200810.1038/ncb172218376396
20.	SM ParkAB GaurE LengyelME PeterThe miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2Genes Dev22894907200810.1101/gad.164060818381893
21.	D KongY LiZ WangS BanerjeeA AhmadHR KimFH SarkarmiR-200 regulates PDGF-D-mediated epithelialmesenchymal transition, adhesion, and invasion of prostate cancer cellsStem Cells2717121721200910.1002/stem.10119544444
22.	L YinK MorishigeT TakahashiK HashimotoS OgataS TsutsumiK TakataT OhtaJ KawagoeK TakahashiH KurachiFasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivoMol Cancer Ther615171525200710.1158/1535-7163.MCT-06-068917513600
23.	JM HarveyGM ClarkCK OsborneDC AllredEstrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancerJ Clin Oncol1714741481199910334533
24.	S UmemuraJ ItohH ItohA SerizawaY SaitoY SuzukiY TokudaT TajimaRY OsamuraImmunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?Appl Immunohistochem Mol Morphol12813200410.1097/00129039-200403000-00002
25.	A WunderlichM FischerT SchlosshauerA RamaswamyBH GreeneC BrendelD DollD BartschS HoffmannEvaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancerCancer Sci102762768201110.1111/j.1349-7006.2011.01853.x
26.	H YingSL BirocWW LiB AlickeJA XuanR PagilaY OhashiT OkadaY KamataH DinterThe Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor modelsMol Cancer Ther521582164200610.1158/1535-7163.MCT-05-044016985048
27.	HJ ChoJ YooRho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cellsCell Biol Int3112251230200710.1016/j.cellbi.2007.04.00617537651
28.	GP SunM KohnoP GuoY NagaiK MiyataYY FanS KimuraH KiyomotoK OhmoriDT LiY AbeA NishiyamaInvolvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injuryJ Am Soc Nephrol1721932201200610.1681/ASN.200512137516790507